Vitiligo is a chronic pigmentary disorder in which melanocytes are destroyed, causing depigmented patches of skin and sometimes hair. It is often associated with autoimmune mechanisms.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Arcutis is in focus after new Phase 3 extension data for Zoryve cream 0.05% in young children with atopic dermatitis and ahead of its Feb. 25 Q4 results. Investors are also watching recent FDA actions and pipeline updates for additional pediatric and dermatology indications.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
Arcutis Biotherapeutics is scheduled to report fourth-quarter and full-year 2025 results on Feb. 25, after market close. Investors will focus on sales performance of Zoryve and pipeline updates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07595939 |
Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo |
NOT_YET_RECRUITING | PHASE3 |
| NCT07533019 |
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo |
RECRUITING | PHASE2 |
| NCT07353801 |
Oral Mini Pulse Dexamethasone in Pediatric Vitiligo |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07152626 |
Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo |
RECRUITING | PHASE2 |
| NCT06602232 |
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06446063 |
Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients. |
TERMINATED | |
| NCT06163326 |
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04822584 |
Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo |
COMPLETED | PHASE2 |
| NCT04338581 |
Evaluation of AMG 714 for Vitiligo |
COMPLETED | PHASE2 |
| NCT04237103 |
Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo |
COMPLETED | PHASE2 |
